Wisconsin Capital Management LLC Decreases Position in Novo Nordisk A/S (NYSE:NVO)

Wisconsin Capital Management LLC lowered its stake in Novo Nordisk A/S (NYSE:NVO) by 0.9% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 68,135 shares of the company’s stock after selling 643 shares during the quarter. Novo Nordisk A/S comprises 4.2% of Wisconsin Capital Management LLC’s portfolio, making the stock its 7th biggest holding. Wisconsin Capital Management LLC’s holdings in Novo Nordisk A/S were worth $7,049,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in NVO. CNB Bank purchased a new stake in shares of Novo Nordisk A/S during the fourth quarter worth about $26,000. Pacific Center for Financial Services grew its position in shares of Novo Nordisk A/S by 100.0% during the third quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock worth $25,000 after purchasing an additional 135 shares in the last quarter. Valued Wealth Advisors LLC purchased a new stake in shares of Novo Nordisk A/S during the fourth quarter worth about $28,000. Copeland Capital Management LLC grew its position in shares of Novo Nordisk A/S by 100.0% during the third quarter. Copeland Capital Management LLC now owns 282 shares of the company’s stock worth $26,000 after purchasing an additional 141 shares in the last quarter. Finally, Bell Investment Advisors Inc grew its position in shares of Novo Nordisk A/S by 79.9% during the third quarter. Bell Investment Advisors Inc now owns 286 shares of the company’s stock worth $26,000 after purchasing an additional 127 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 0.3 %

Shares of NYSE NVO traded down $0.36 during trading hours on Thursday, hitting $125.80. 3,431,971 shares of the company traded hands, compared to its average volume of 4,816,638. The stock has a market capitalization of $564.53 billion, a price-to-earnings ratio of 46.51, a price-to-earnings-growth ratio of 2.15 and a beta of 0.41. The company has a current ratio of 0.82, a quick ratio of 0.64 and a debt-to-equity ratio of 0.19. The company’s 50 day moving average price is $126.80 and its 200 day moving average price is $111.74. Novo Nordisk A/S has a 12 month low of $75.56 and a 12 month high of $138.28.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share for the quarter, beating the consensus estimate of $0.66 by $0.05. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. The firm had revenue of $9.51 billion for the quarter, compared to the consensus estimate of $9.14 billion. On average, equities research analysts anticipate that Novo Nordisk A/S will post 3.32 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently disclosed a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Investors of record on Monday, March 25th were issued a dividend of $0.664 per share. The ex-dividend date was Friday, March 22nd. This represents a yield of 0.9%. This is a boost from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. Novo Nordisk A/S’s payout ratio is presently 49.17%.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Morgan Stanley assumed coverage on Novo Nordisk A/S in a research report on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 target price for the company. UBS Group assumed coverage on Novo Nordisk A/S in a research note on Tuesday, January 16th. They issued a “neutral” rating on the stock. BMO Capital Markets assumed coverage on Novo Nordisk A/S in a research note on Friday, April 12th. They issued an “outperform” rating and a $163.00 price objective on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Thursday, April 18th. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $133.60.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.